Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

Launched by UNIVERSITY OF CHICAGO · Mar 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat prostate cancer by combining two methods: focal prostate ablation therapy, which is a type of surgery that targets and removes cancer cells in a specific area of the prostate, and androgen deprivation therapy, which is a hormone treatment that lowers male hormones that can fuel cancer growth. The goal of this research is to see how safe and effective this combination treatment is for men with intermediate-risk prostate cancer.

To be eligible for this trial, participants must be men aged 65 to 74 who have been diagnosed with intermediate-risk prostate cancer, meaning their cancer is not too advanced and has specific characteristics that make it suitable for this study. They should not have evidence of cancer spreading beyond the prostate and must be healthy enough to undergo the treatments. Those who join the trial can expect to receive the combination of therapies, and their progress will be monitored to assess how well the treatments are working and if there are any side effects. This trial is currently recruiting participants, and it's a chance to explore a potentially promising treatment option for prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• * Subjects must have intermediate-risk PCa as defined by the below criteria:
• • a. Favorable intermediate-risk PCa: i. ≤ clinical stage T2c, GG2, and PSA ≤ 10 ng/mL, and \<50% positive biopsy cores with PCa b. Unfavorable intermediate-risk PCa: i. ≤ clinical stageT2c, GG2, and PSA 10-20 ng/mL, or ≥50% positive biopsy cores with PCa, or ii. ≤ clinical stage T2c, GG3, and PSA \< 20 ng/mL
• • No mpMRI evidence of extra-prostatic extension (EPE) or seminal vesicle invasion, and if seminal vesical invasion is suspected, it must be excluded by prostate biopsy.
• • Subjects must have chosen to get Focal Therapy for the treatment of prostate cancer.
• • Subjects must have confirmed non-metastatic PCa following SOC screening for patients with unfavorable intermediate-risk PCa, a combination of computed tomography imaging of the abdomen and pelvis (CTAP) and technetium-99-mDP nuclear medicine bone scan (BS) and/or prostate-specific membrane antigen positron emission tomography (PSMA/PET) scan prior to enrollment. The imaging studies should be obtained within 6-months of enrollment. Additional imaging is not required for men with favorable intermediate-risk PCa.
• • Subject must be male ≥ 18 years-old.
• • Subjects must have a life expectancy of at least 10-years per the opinion of the treating investigator.
• • Subjects must be designated as Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 or Karnofsky Performance Status Scale Score ≥ 60%, see Appendix A).
• • Subjects must be fit to undergo general anesthesia and the FT surgical procedure, which includes adequate visualization of the prostate gland on transrectal ultrasound imaging, access to the urethra, perineum and rectum, as well as be tolerant of lithotomy positioning in the opinion of the treating investigator or the operating surgeon(s) if not the same as the treating investigator.
• * Subjects must have adequate organ and marrow function as defined below:
• • Hemoglobin ≥ 10 g/dL Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN Creatinine \< 1.5 institutional ULN OR Calculated or measured creatinine clearance \> 50 mL/min/1.73 m2 eGFR \>30 mL/min using the MDRD (modification of diet and renal disease) formula Serum albumin ≥3.0 g/dL Serum potassium ≥3.5 mmol/L
• • Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• • Subjects who are sexually active with a woman of childbearing potential must agree to use a condom with spermicidal foam/gel/film/cream/suppository and his partner must also be practicing a highly effective method of contraception (i.e., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system) during treatment and for 3-months following the last ADT treatment.
• • Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa. Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
• • Subjects with locally advanced, nodal or metastatic prostate cancer.
• • Subjects who are unfit for pelvic mpMRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute to significant image artifacts, allergy or contraindication to gadolinium contrast agent.
• • History of allergy or intolerance to study drug components.
• • History of bilateral orchiectomy.
• • If the subject has an uncontrolled or major debilitating inter-current illness.
• • Subjects who are receiving any other investigational agents, or who have received other investigational agents in the past and who are no longer receiving these investigational agents may be eligible at the discretion of the principal investigator (PI).
• • Judgment by the treating investigator or PI that the subject is unsuitable to participate in the study and the subject is unlikely to comply with study procedures, restrictions and requirements.